Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Byfavo vs Propofol for Rigid Bronchoscopy
NCT05835713Withdrawn
- Sponsor
- Samsung Medical Center
- Start
- Apr 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
01
Overview
Randomised trial of remimazolam in Respiratory Disease (RD), tracheal stenosis (TS) and endobronchial mass (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Duration of emergence after rigid bronchoscopy at 10 minutes. Planned start Apr 2023; status: withdrawn.
02
Drugs
remimazolam
03
Conditions
Respiratory Disease (RD)tracheal stenosis (TS)endobronchial mass
Beyond the preview
Go deeper on NCT05835713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835713.